Loading…
* Free cash flow = OCF − net investing outflow (the filings carry no standalone capex line).
Operates in Pharma — Distribution. Per the activity note to the FY2024 annual report, the company imports and exports medicines within Georgia and to Azerbaijan, Ukraine, Kazakhstan, Kyrgyzstan, Turkmenistan, Belarus, and Moldova.
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | CAGR |
|---|---|---|---|---|---|---|---|
| Total Revenue | 3,879 | 20,660 | 18,645 | 16,723 | 18,080 | 14,515 | +30.2% |
| Total COGS | 2,397 | 12,800 | 13,988 | 14,568 | 13,542 | 13,412 | +41.1% |
| Gross Profit | 1,482 | 7,861 | 4,658 | 2,156 | 4,538 | 1,103 | -5.7% |
| Gross Margin | 38.2% | 38.0% | 25.0% | 12.9% | 25.1% | 7.6% | |
| 23 | 52 | 111 | 183 | 216 | 195 | +53.8% | |
| EBITDA | 1,460 | 7,809 | 4,546 | 1,973 | 4,321 | 907 | -9.1% |
| EBITDA Margin | 37.6% | 37.8% | 24.4% | 11.8% | 23.9% | 6.3% | |
| Total D&A | 0 | 1 | 7 | 6 | 5 | 4 | +50.0% |
| EBIT / Operating Income | 1,460 | 7,808 | 4,540 | 1,967 | 4,316 | 903 | -9.2% |
| Total Other Income | 0 | 197 | 968 | 1,447 | 3,563 | 1,541 | nmf |
| Profit Before Tax | 1,460 | 8,004 | 3,572 | 520 | 754 | 638 | nmf |
| Total Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | |
| Net Profit / (Loss) | 822 | 6,501 | 3,572 | 520 | 754 | 638 | nmf |
| Net Margin | 21.2% | 31.5% | 19.2% | 3.1% | 4.2% | 4.4% |
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Ownership & directors from companyinfo.ge (public corporate registry).
Ranked by how close each latest revenue is to this one — not a curated comp set. Open this set in Compare →